Science of Psychiatric Drugs

Researchers argue for a shift away from a focus on antipsychotic adherence toward understanding service users’ diverse patterns of use.

The CHR-P model focuses on “attenuated psychosis” to predict “transition” to schizophrenia and ignores other factors. But new research shows that the model is a poor predictor.

Evolutionary theorists suggest that antidepressants interfere with the adaptive function of depression and propose a test of this theory.

A researcher and service user Stevie Lewis recounts her own experience with antidepressant withdrawal and what she wishes her doctors knew.

Researchers push for a renewed focus on true shared decision-making for patients diagnosed with psychosis.

Researchers again debunk the claim that the FDA black box warnings on antidepressants led to more suicides.

“Short and simple psychological programs can prevent people from relapsing when they stop their antidepressants.”

The prominent psychiatrist explores why antidepressants remain highly overprescribed and offers solutions to the problem.

Researchers have found further evidence that the anticholinergic effect of psychiatric drugs can lead to cognitive impairments.

The FDA collaborated with Biogen to conduct repeated re-analyses of aducanumab for Alzheimer's and FDA committee members are raising concerns.

Medical researchers present evidence that ADHD is overdiagnosed in children and teens, which can lead to significant harm.

While professional guidelines recommend antidepressants for back pain, researchers point out the lack of evidence for their usefulness.

Researchers find a lack of current literature on safe, effective ways to manage antidepressant withdrawal and make suggestions for future research.

The article suggests that research challenging the evidence for ADHD drugs does not lead to changes without public campaigns.

After 15 years, the founder of SurvivingAntidepressants.org, Adele Framer, shares what she has learned about the science of withdrawing from psychiatric drugs.

Adverse physiological symptoms of antidepressant withdrawal are regularly mistaken to be other problems to the detriment of the patient.

Bias and financial conflicts in antidepressant trials “contribute to systematic underestimation of risk in the published literature.”

Due to lackluster antidepressant study results, researchers test if subgroups of depressed patients show greater improvement.

Qualitative study finds that both internal resources and systemic factors play a role in antipsychotic discontinuation outcomes.

The recent report by the BBC on medication-free treatment in Norway, when viewed in conjunction with the media silence on Martin Harrow's latest publication, reveals why the public remains misinformed about the long-term effects of antipsychotics.

People with "serious mental illness" who stop taking antipsychotics are more likely to recover, even when accounting for baseline severity.

Online communities are stepping in to help people facing withdrawal effects amass information and receive support for their withdrawal experiences.

Protracted Withdrawal Syndrome characterized by long-term adverse experiences after coming off of antidepressants.

An analysis of FDA adverse event reports related to esketamine shows the potential for negative effects such as suicidal and self-injurious ideation.

New research finds that antidepressants are not effective for bipolar disorder and can worsen symptoms of mania.